Marion Ohlmann

Title: The Innovative Contributions of Marion Ohlmann

Introduction

Marion Ohlmann, a prominent inventor based in Münich, Germany, has made significant strides in the field of biotechnology. With six patents to her name, she has demonstrated a remarkable ability to innovate and improve upon existing technologies, particularly in the realm of recombinant vaccinia viruses. Her work continues to contribute to advancements in vaccine development and gene therapy.

Latest Patents

Among her latest patents, Marion Ohlmann has developed innovative techniques relating to the recombinant modified vaccinia virus Ankara (MVA). Her patents encompass the creation of recombinant vaccinia viruses capable of expressing foreign genes. This groundbreaking work provides a platform for producing polypeptides, including antigens and therapeutic agents, thereby facilitating the development of vaccines and viral vectors for gene therapy. Such advancements highlight her essential role in enhancing medical technologies.

Career Highlights

Marion Ohlmann has been associated with esteemed institutions, including the GSF-Forschungszentrum für Umwelt und Gesundheit, GmbH. Her impressive career is marked by her dedication to research in environmental health and her transformative work in virology, which has led to the protection of her inventions through patents.

Collaborations

Throughout her career, Marion Ohlmann has collaborated with notable professionals in her field, including Gerd Sutter and Volker Erfle. These partnerships have fostered a creative exchange of ideas and enhanced the research outcomes, paving the way for innovative developments in biotechnology.

Conclusion

As a leading inventor, Marion Ohlmann continues to shape the future of biotechnology through her pioneering patents and collaborative efforts. Her contributions not only advance scientific knowledge but also hold the promise of improved therapeutic solutions for global health challenges.